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Abstract 
Background: Oseltamivir is the only antiviral treatment recommended for influenza in young children over the age 
of 1 year. There is scant data on oseltamivir pharmacokinetics (PK) in infants <1 year. We set out to perform PK meas-
urements in infants who received oseltamivir.
Methods: This study was a prospective, uncontrolled, open label evaluation of the pharmacokinetics of oseltamivir 
metabolism, safety of oseltamivir, viral clearance in infants <12 months diagnosed with influenza by nasopharyn-
geal influenza nucleic acid antigen test (NAAT). Blood levels of the prodrug oseltamivir and its active carboxylate 
were measured prior to a dose of oseltamivir and at 4 time points afterwards, to calculate Cmax (ng/mL), Tmax (h), 
AUC0−t (ng h/mL) and time for AUC (h).
Results: Four children with influenza A received oral oseltamivir, 2.35–3 mg/kg/dose. This dose range produced a 
target oseltamivir carboxylate plasma concentration in excess of the proposed 12-h target AUC of 3800 ng h/mL, 
selected from earlier studies to avert resistance. One patient developed GIT adverse event: dry retching.
Conclusion: Oseltamivir was well tolerated at a dose of 2.35–3 mg/kg/dose twice a day in infants under the age of 
1 year. In general agreement with earlier data, these doses produced a target oseltamivir carboxylate plasma exposure 
in excess of the proposed 12-h target exposure of AUC equal to 3800 ng h/mL in two patients. The limited plasma 
concentration data in the remaining two patients were not inconsistent with the target exposure being reached.
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Background
Infants and young children are particularly prone to 
influenza morbidity [1–3]. Influenza morbidity in young 
children and infants ranges from school absenteeism to 
acute respiratory distress requiring hospitalisation, and 
can result in death from complications [1]. Oseltamivir 
is currently the only antiviral treatment recommended 
in young children, usually for those aged 1–5 years [4–6]. 
It inhibits the envelope protein neuraminidase, blocking 
release of viral progeny from infected cells, preventing 
subsequent entry into uninfected cells [7]. If commenced 
within 48 h of symptom onset, oseltamivir reduces both 
duration and complications of influenza [8, 9], although 
some dispute this [10, 11]. In December 2012, the use of 
oseltamivir for influenza treatment, but not for prophy-
laxis, was approved by the FDA for infants as young as 
2  weeks, previously having temporary approval for use 
in infancy during the 2009 pandemic, from April 2009 
to June 2010 [12, 13]. Routine use of oseltamivir in 
infants <1 year of age has been limited by both a lack of 
pharmacokinetic (PK) data and concern about adverse 
events [14–17].
The ontogeny of pharmacokinetic functions has 
potential dosing implications in infants [18, 19]. 
Oo et  al. proposed a dose of 2–3  mg/kg in infants 
6–12  months of age, given that renal and hepatic clear-
ance of oseltamivir adjusted for body surface area reach 
adult levels by 6–9/12 of age [20]. The only known pub-
lished data regarding oseltamivir pharmacokinetics in 
infants <1 year old is by Kimberlin et al. [21]. They rec-
ommended doses of 3.0  mg/kg twice a day (BID) for 
infants less than 8  months old, and 3.5  mg/kg BID for 
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infants 9–11 months, based on evidence that these doses 
achieve an oseltamivir carboxylate 12 h area-under-the-
curve (AUC) target of 3800  ng  h/mL, and promote less 
oseltamivir resistance than lower doses [21–24]. The 
FDA recommends 3 mg/kg BID for infants <1 year of age 
[25].
During the 2011 influenza season at the Children’s Hos-
pital, Westmead (CHW) in Sydney, Australia, pharma-
cokinetic data was collected from a series of four infants 
admitted to intensive care and treated with oseltamivir.
Methods
Study population
Infants aged <12 months who warranted treatment with 
oseltamivir for influenza-like illness were included. The 
Sydney Children’s Hospitals Network Human Research 
Ethics Committee provided ethics approval (approval 
number: HREC/10/CHW/61). All patients or caregivers 
signed informed consent forms.
Study design and end points
This study was a prospective, open label evaluation of 
the pharmacokinetics of oseltamivir metabolism, safety 
of oseltamivir, viral clearance. The oseltamivir dose pre-
scribed was at the attending clinician’s discretion.
Pharmacokinetic analysis
Specific recommendations were made for the timing 
of blood samples to measure levels of oseltamivir and 
oseltamivir carboxylate. However, to minimize the num-
ber of tests and patient discomfort, samples were col-
lected at the same time as clinically required samples, 
whenever possible. Recommended times of sample col-
lection were within 15 min prior to an oseltamivir dose, 
1 h ± 15 min, 2–3 h, 5–7 h and 10–12 h post dose. The 
blood volume required for plasma level determination 
was 500 µL. Blood was collected into a sodium fluoride/
EDTA collection tube, placed on ice and centrifuged 
(1500  g at 4  °C for 10  min). Plasma was stored at −70 
to −80  °C before despatch to the laboratory (PRA Early 
Development Services, Inc. Kansas, USA). Oseltamivir 
and oseltamivir carboxylate concentrations were deter-
mined by high-performance liquid chromatography with 
tandem mass spectrometric detection [18].
We adopted a desirable target exposure value proposed 
by Kimberlin of an AUC12 for oseltamivir carboxylate of 
3800 ng h/mL [21]. For computational purposes, concen-
trations at t = −15  min were taken as concentration at 
zero time. Non-compartmental analysis was conducted 
using PKSolver, a published pharmacokinetic analysis 
Excel plugin [26] to obtain estimates of exposure includ-
ing AUC0−t and Cmax. A set of 5 time-points from zero 
to 10 h in the 6th dose cycle was available for two of the 
four patients while for the other two patients only two 
time-points were available each, for one patient in the 7th 
dose-cycle and for the other patient in the 8th dose-cycle. 
It can be assumed that the patients were at steady-state 
by this time hence the sparsely sampled data may still 
give an impression of the exposure to oseltamivir carbox-
ylate in these patients.
Virological analysis
Each nasopharyngeal swab or aspirate was obtained 
using a sterile synthetic tip swab, with a plastic or alu-
minium shaft, and inserted into vials containing sterile 
viral transport medium. These were collected at treat-
ment initiation and analysed at the Children’s Hospital, 
Westmead; Sydney, Australia. Influenza was diagnosed 
and strain type determined using nucleic acid amplifica-
tion testing (NAAT) by polymerase chain reaction (PCR).
Safety evaluation
An adverse event was defined as any untoward medi-
cal occurrence in a patient which may or may not have 
a causal relationship with the administered oseltamivir. 
The following biomarkers were assessed during oseltami-
vir treatment and compared to pre-treatment levels: 
serum creatinine, electrolytes, liver transaminases (AST, 
ALT), alkaline phosphatase, total bilirubin level and full 
blood count.
Results
Four children received oral oseltamivir: three at 3 mg/kg 
twice a day (bd) and one at 2.35 mg/kg bd.
All four patients were infected with influenza A, 
patients 1–3 were H1N1 and the strain was not docu-
mented for the patient 4.
The following table presents the pharmacokinetic 
parameters for oseltamivir in these four patients 
(Table 1).
From the AUC0−t estimates, the first two patients (1 
and 2) attained oseltamivir carboxylate plasma concen-
trations in excess of the proposed 12-h target AUC value 
for antiviral therapy during the 0 to approximately 10-h 
period; it can be surmised that a 0–12 h AUC exposure 
value would also be in excess of the proposed thera-
peutic target given these AUC0−t values (Fig.  1). The 
two patients with only two samples per dose cycle were 
exposed to 1747 and 2156  ng  h/mL for periods of 2.3 
and 6.5 h, respectively. These levels of exposure are not 
inconsistent with adequate oseltamivir carboxylate expo-
sure sufficient to provide effective therapy given the pro-
posed target AUC12 of 3800 ng h/mL, but further plasma 
time points would have allowed for confirmation.
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All patients recovered from acute influenza during 
their intensive care unit admissions. One infant suffered 
an adverse event: self-limited dry retching (Table 2).
Discussion
Our results are consistent with the proposition that a 
dose of 2.35–3 mg/kg produced a target oseltamivir car-
boxylate plasma concentration in excess of the proposed 
12-h target AUC of 3800 ng h/mL.
Oseltamivir is well absorbed from an early age. Ani-
mal studies demonstrate a rapid increase of the trans-
port protein at birth, and a widespread distribution for 
oseltamivir including good penetration of lung tissue, 
the middle ear and the nasal mucosa [27]. It is metabo-
lized to the active metabolite oseltamivir carboxylate by 
the liver carboxylesterase HCE1 [19, 27]. Production of 
HCE1 is lower in foetuses than in infants <1 year of age, 
who in turn have lower gene transcription than children 
1–10 years [18]. However, much inter-individual variabil-
ity exists, particularly in the younger age groups. Young 
children have greater proportionate extracellular fluid and 
thus a greater volume of distribution (VD) of oseltamivir 
carboxylate, resulting in a lower circulating plasma con-
centration compared to older children and adults [27]. 
Oseltamivir carboxylate is not extensively protein bound 
and, thus, immaturity of plasma protein levels does not 
impact on VD [27]. Animal studies indicate good pen-
etration of oseltamivir carboxylate into respiratory tissues 
[19]. Oseltamivir has been linked to neuropsychiatric side 
effects in children and young adults, especially in Japan, 
although it is unclear whether the encephalopathy was 
induced by influenza or by its treatment [28, 29]. Both rat 
and human foetus studies showed certain central nerv-
ous system (CNS) efflux pumps to be in low numbers 
at birth and increase with age, whilst others are present 
from the second trimester [19]. There was, however, no 
accumulation of oseltamivir carboxylate in the brains of 
healthy rats. Oseltamivir is filtered and actively excreted 
from the renal tubules using OAT transporter proteins 
[27]. Clearance function of these proteins is low at birth 
and increases over the first year of life, which may lead to 
reduced oseltamivir clearance in neonates [27]. Oo et al. 
demonstrated that oseltamivir carboxylate clearance 
adjusted for body surface area (BSA) reached adult levels 
by 6–9 months of age, whilst a higher BSA-to weight ratio 
in those 1–2 years resulted in higher clearance and conse-
quently lower peak plasma concentration (Cmax), time to 
reach Cmax (Tmax) and AUC compared to those 3–5 years 
Fig. 1 Plasma-time curves for oseltamivir carboxylate in four infants
Table 2 Adverse events (AE) in children receiving oral oseltamivir




Comorbidities Clinical AE Laboratory changes
1 6 m, 23 d Tetralogy of Fallot D1
Dry-retching
Day 1 bloods: raised creatinine (48 mmol/L) 
and AST (66 mmol/L)
Attributed to cardiac condition
Normalised after frusemide dose during 
course of oseltamivir




Severe OSA due to epiglottis dystrophy
Nil Nil





Nil Baseline bloods normal
D2 of oseltamivir: rising creatinine, urea, 
AST/ALT/GGT
All parameters normalised 10 days after first 
dose
Laboratory abnormalities attributed to HUS
4 3 m, 13 d Exomphthalmos Nil Nil
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[20]. Kimberlin et al. achieved their target AUC with doses 
of 3 mg/kg in those up to 9 months of age whereas those 
9–11 months of age required a higher dose of 3.5 mg/kg, 
due to greater oseltamivir carboxylate clearance over the 
first year of life [21]. Thus, oseltamivir clearance may peak 
around 12 months, and then reduce after 3 years.
There was one GIT side effect (dry-retching) from 
oseltamivir in our cohort. Laboratory anomalies were 
attributable to comorbidities. Likewise, a dose of 
3–3.5 mg/kg of oseltamivir was well tolerated in 87 infants 
with no premature drug discontinuation [21]. Of eight 
adverse events (AE) deemed related to oseltamivir (9.1 %), 
five were emesis, two developed a rash and one developed 
a serious AE: cutaneous hypersensitivity. There were no 
CNS AE. In another trial, 11 infants who received a rather 
high median dose of 5.5  mg/kg/dose of oseltamivir suf-
fered no serious adverse events, and all completed the 
course [30]. Two developed a rash, two gastrointestinal 
side effects and three had transiently raised liver transami-
nases that normalised within 2 weeks of completing ther-
apy. In a report of 35 patients <1 year of age who received 
oseltamivir, no AE occurred and no effect on liver function 
was detected [31]. In a report of 5 premature infants, mean 
gestational age 31  weeks, who received oseltamivir at 
2–3 mg/kg/dose, there were no treatment related AE [32].
Conclusion
Oseltamivir was well tolerated at a dose of 2.35–3 mg/kg/
dose twice a day in infants under the age of 1 year. These 
doses were confirmed to produce a target oseltamivir car-
boxylate plasma exposure in excess of the proposed 12-h 
target exposure of AUC 3800  ng  h/mL in two patients 
and the limited plasma concentration data in the remain-
ing two patients were not inconsistent with the target 
exposure being reached.
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